Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23495312 | 0.82 | USP2 (0.73) | KDM4EKMT2AMEN1CYP2D6MAPT | |
| SCHEMBL16117950 | 0.77 | KDM4E (0.69) | KDM4EKMT2AMEN1CYP2D6CYP3A4 | |
| SCHEMBL23495158 | 0.77 | KDM4E (0.62) | KDM4EKMT2AMEN1CYP2D6CYP3A4 | |
| SCHEMBL23495234 | 0.77 | KDM4E (0.62) | KDM4EKMT2AMEN1CYP2D6CYP3A4 | |
| SCHEMBL23495325 | 0.77 | ALDH1A1 (0.58) | KMT2AMEN1MAPTALOX15ALDH1A1 | |
| SCHEMBL23495470 | 0.77 | ALDH1A1 (0.58) | KDM4EKMT2AMEN1CYP2D6CYP3A4 | |
| SCHEMBL23495345 | 0.76 | ALDH1A1 (0.59) | KDM4EKMT2AMEN1CYP2D6CYP3A4 | |
| SCHEMBL23495174 | 0.76 | KDM4E (0.63) | KDM4EKMT2AMEN1CYP2D6CYP3A4 | |
| SCHEMBL23495210 | 0.76 | ALDH1A1 (0.59) | KMT2AMEN1MAPTALOX15ALDH1A1 | |
| SCHEMBL23495253 | 0.75 | LMNA (0.58) | KDM4EMAPTALDH1A1USP2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149621-B1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS INC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20230150977-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150977-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021231572-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150977-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, IL1B, IL1RN | KDM4E 3412/4885KMT2A 3926/4885MEN1 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.